Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM)

Study Of Valproic Acid To Treat TSP/HAM Patients In Sao Paulo, Brazil

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00681980

Enrollment

Registered

2008-05-21

Start date

2008-02-29

Completion date

2015-12-31

Last updated

2015-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paraparesis Spastic Tropical

Keywords

TSP/HAM, HTLV-1, treatment

Brief summary

Is the valproic acid efficacy to treat TSP/HAM

Interventions

DRUGValproic acid

15 mg/kg/day

DRUGcosticosteroids

metypredsolone 1 g/day

DRUGvalproid acid plus corticosteroids

valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* HTLV-1; TSP/HAM fulfill criteria

Exclusion criteria

* Age \<18 years

Design outcomes

Primary

Measure	Time frame
Neurological sacles	24 months

Secondary

Measure	Time frame
Quality of life	2009

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026